Compare · DHR vs MLAB
DHR vs MLAB
Side-by-side comparison of Danaher Corporation (DHR) and Mesa Laboratories Inc. (MLAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DHR and MLAB operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- DHR is the larger of the two at $144.26B, about 266.6x MLAB ($541.1M).
- DHR has been more active in the news (5 items in the past 4 weeks vs 1 for MLAB).
- DHR has more recent analyst coverage (25 ratings vs 3 for MLAB).
- Company
- Danaher Corporation
- Mesa Laboratories Inc.
- Price
- -
- -
- Market cap
- $144.26B
- $541.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 1
- Recent ratings
- 25
- 3
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Mesa Laboratories Inc.
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Latest DHR
- VP, Chief Accounting Officer Bouda Christopher covered exercise/tax liability with 60 shares, decreasing direct ownership by 0.65% to 9,107 units (SEC Form 4)
- Director Filler Linda exercised 3,298 shares at a strike of $71.88 and covered exercise/tax liability with 1,181 shares, increasing direct ownership by 9% to 26,829 units (SEC Form 4)
- Director Zerhouni Elias A. exercised 3,298 shares at a strike of $71.88 and covered exercise/tax liability with 1,181 shares, increasing direct ownership by 5% to 45,303 units (SEC Form 4)
- Audax Private Equity and Linden Capital Partners Agree to Sell StatLab Medical Products to Leica Biosystems
- Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
- Danaher Schedules Second Quarter 2026 Earnings Conference Call
- Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner
- SEC Form 11-K filed by Danaher Corporation
- Piper Sandler initiated coverage on Danaher with a new price target
- Danaher Completes Acquisition of Masimo Corporation
Latest MLAB
- MESA LABS DECLARES QUARTERLY DIVIDEND
- CAO Crennen Lyndsey Elizabeth sold $39,560 worth of shares (442 units at $89.50), exercised 726 shares at a strike of $95.10 and was granted 263 shares, increasing direct ownership by 37% to 2,020 units (SEC Form 4)
- SVP Operations Archbold Brian David exercised 3,324 shares at a strike of $95.10, was granted 1,859 shares and sold $225,187 worth of shares (2,516 units at $89.50), increasing direct ownership by 72% to 6,377 units (SEC Form 4)
- CFO Sakys John exercised 3,792 shares at a strike of $95.10, was granted 2,282 shares and sold $253,022 worth of shares (2,827 units at $89.50) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 19,785 units (SEC Form 4)
- SVP Operations Archbold Brian David sold $116,558 worth of shares (1,151 units at $101.27), decreasing direct ownership by 24% to 3,710 units (SEC Form 4)
- CAO Crennen Lyndsey Elizabeth sold $11,950 worth of shares (118 units at $101.27), decreasing direct ownership by 7% to 1,473 units (SEC Form 4)
- CFO Sakys John sold $123,850 worth of shares (1,223 units at $101.27), decreasing direct ownership by 7% to 16,538 units (SEC Form 4)
- New insider Crennen Lyndsey Elizabeth claimed ownership of 1,863 shares (SEC Form 3)
- SVP Operations Archbold Brian David exercised 2,454 shares at a strike of $104.08, increasing direct ownership by 102% to 4,861 units (SEC Form 4)
- CFO Sakys John exercised 2,717 shares at a strike of $104.08, increasing direct ownership by 18% to 17,761 units (SEC Form 4)